Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.20.

Several equities research analysts have weighed in on SENS shares. Wall Street Zen upgraded shares of Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Mizuho reduced their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Finally, Weiss Ratings cut shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 12th.

Insider Transactions at Senseonics Holdings, Inc. Common Stock

In other news, Director Douglas Roeder acquired 13,953 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction on Wednesday, August 19th. The shares were purchased at an average price of $8.98 per share, with a total value of $125,297.94. Following the acquisition, the director owned 171,191 shares in the company, valued at $1,537,295.18. This represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new position in Senseonics Holdings, Inc. Common Stock in the second quarter valued at about $36,000. Ausdal Financial Partners Inc. raised its holdings in Senseonics Holdings, Inc. Common Stock by 50.0% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares during the last quarter. GSK plc bought a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth about $60,000. The Manufacturers Life Insurance Company acquired a new position in Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at about $65,000. Finally, State of Wyoming acquired a new position in Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at about $67,000. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Holdings, Inc. Common Stock Price Performance

Senseonics Holdings, Inc. Common Stock stock opened at $8.79 on Friday. The business’s fifty day moving average is $7.01 and its two-hundred day moving average is $6.70. The company has a debt-to-equity ratio of 0.62, a quick ratio of 6.40 and a current ratio of 6.74. The firm has a market cap of $367.42 million, a P/E ratio of -3.94 and a beta of 1.08. Senseonics Holdings, Inc. Common Stock has a 52 week low of $4.79 and a 52 week high of $11.58.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. The business had revenue of $14.48 million during the quarter. Equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.29 earnings per share for the current fiscal year.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.